The first opportunity related to regulatory change is the
generic EpiPen market. (https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm617173.htm)
This topic is well reported on due to the lack of availability of name brand
epipens. (https://abcnews.go.com/Health/epipen-shortage-generic-version/story?id=57288176)
These reports made me believe there is an opportunity here because the shortage
needs to be filled. While I do not need epipens I have done research on generic
epipens, for investing purposes, and found that the FDA has started approving generic
epipens which will increase the opportunity in the market. The protypical
customer for the product will be epipen users.
Another good opportunity related to regulatory change is the
marijuana industry. With Canada set to legalize recreational marijuana in
October, there have been many economic and regulatory opportunities associated
with it. An example of this would be Constellation Brands heavily investing in Canopy
Growth Corp since it is set to become legal. (https://www.forbes.com/sites/greatspeculations/2018/08/20/what-constellation-brands-massive-investment-in-canopy-growth-corp-means-for-both-companies/#6ced610373df)
Furthermore, anyone can invest in marijuana companies on stock exchanges,
giving people a great economic opportunity. I see the opportunity in this as
well because it is a new market with massive potential to rapidly expand.
The second opportunity relating to economic trends would be the current bull market that we are in and should continue to be in. (https://www.cnbc.com/2018/09/11/jeff-saut-bull-market-should-have-another-7-to-8-years-left.html) This gives people a great opportunity to invest in stocks and take advantage of this economic opportunity. I know this opportunity exists due to my personal stock portfolio being up more than 60% in the last 10 months.
Matt,
ReplyDeleteI agree with you when you say that the Epipen market has a shortage for consumers. However, I believe that the companies that produce the Epipen's are doing this on purpose so that they can charge whatever price they want. In my post, I wrote about how regulations are being dissolved in the medical device industry to spur more economic competition. With these rules going away, other companies have the ability to create their own Epipen that can compete with others on the market.
Matt, your economic opportunity for EpiPens is relatable to me on a personal level. I have a friend from my hometown who has grown up with diabetes and knows the struggle of finding inexpensive medical supplies. With regulations changing in this market to get away from this type of price gauging, there a business opportunity available to provide a more affordable solution.
ReplyDelete